Food/Recall·openFDA/food

Honeyville, Inc — Class I: (BULK) SPL-BEV Banana CWT (Banana Smoothie); Super Sack Tote Item# 355-0099

HighPublished Jun 3, 2026· AI-analyzed Jun 8, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Honeyville, Inc. has initiated a Class I recall for bulk Banana Smoothie mix (Item# 355-0099) packaged in Super Sack Totes. The recall was triggered after the firm identified that a potentially Salmonella-contaminated ingredient was used during the manufacturing process.

Who it affects

This affects Honeyville, Inc., its industrial customers who purchased bulk beverage bases, and food safety/quality departments responsible for ingredient qualification and pathogen control.

Why it matters

The Class I classification indicates a high risk of serious adverse health consequences or death from Salmonella exposure. This incident highlights a failure in supplier ingredient control or raw material testing, potentially necessitating a significant review of Hazard Analysis and Risk-Based Preventive Controls (HARPC) programs for the involved facility.

Practical takeaway

QA and procurement teams should audit supplier verification programs to ensure raw materials are screened for pathogens before entering production. Immediate isolation of any remaining inventory of Item# 355-0099 is required. Review traceability protocols to ensure rapid identification of downstream products if bulk ingredients are compromised.

FDA source material

Class I. Reason: Firm received and used potentially contaminated (Salmonella) ingredient to manufacture various products.. Product: (BULK) SPL-BEV Banana CWT (Banana Smoothie); Super Sack Tote Item# 355-0099. Firm: Honeyville, Inc (Ogden UT United States). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.